Roivant Sciences Ltd (NAS:ROIV)
$ 11.57 -0.26 (-2.2%) Market Cap: 8.56 Bil Enterprise Value: 3.46 Bil PE Ratio: 2.08 PB Ratio: 1.58 GF Score: 59/100

Roivant Sciences Ltd at Bank of America Global Healthcare Conference Transcript

May 11, 2023 / 05:40PM GMT
Release Date Price: $9.05 (-1.95%)
Chi Meng Fong
BofA Securities, Research Division - VP and Research Analyst

Good morning, everyone. Welcome to the BofA Healthcare Conferences. My name is Chi. I work with Jason Gerberry, who is the senior analyst here covering SMid Biotech and Spec Pharma and we are pleased to host Roivant Sciences today. And we have here with us is Richard Pulik, CFO of the company. Thanks for joining us.

Richard Pulik
Roivant Sciences Ltd. - CFO

Thank you so much for having me.

Chi Meng Fong
BofA Securities, Research Division - VP and Research Analyst

So maybe to start off for audience who's not familiar with the company. Maybe talk a little bit about what Roivant Sciences does as a company and the business model that you guys have.

Richard Pulik
Roivant Sciences Ltd. - CFO

Great. Yes. Thanks again for the invitation and for having us here. Look, Roivant, I would say, has one of the most exciting I&I portfolios out there. We have -- with $15 billion in peak sales potential

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot